Seres Therap (MCRB)
Seres Therapeutics, Inc., a clinical-stage company, focuses on developing biotherapeutics for serious diseases. The company develops SER-155, an investigational...
- Open
- 4.440
- High
- 4.530
- Low
- 4.315
- Prev. Close
- 4.510
- Volume
- 71.42K
- Turnover
- 314.31K
- Avg Price
- 4.401
- Bid/Ask Ratio
- --
- Amplitude
- 4.77%
- 52wk High
- 29.980
- Volume Ratio
- 1.51
- Turnover Ratio
- 0.82%
Seres Therap Analyst Rating
View moreForecast & Rating
Aug 5, 2026Price forecast
$17.00291.71%
Forecast & RatingStrong buy
2analysts
- Strong buy100.00%
- Buy0.00%
- Hold0.00%
- Sell0.00%
- Strong sell0.00%
News
- TradingView · Aug 5 at 09:41 AM
Seres Therapeutics, Inc. 2Q 2026: Revenue $0.736M, Net income $4.581M, EPS $0.47— 10-Q Summary
- Tip Ranks · Aug 5 at 09:36 AM
Seres Therapeutics (MCRB) Receives a Buy from H.C. Wainwright
- TradingKey · Aug 5 at 06:51 AM
Seres Q2 2026 Earnings: A $25 Million VOWST Gain Drives Quarterly Profit
- Earnings Watch · Aug 5 at 06:06 AM
Seres Therap | 8-K: FY2026 Q2 Revenue Beats Estimate at USD 736 K
- PUBT · Jul 8 at 03:08 PM
Seres Therapeutics holds annual shareholder meeting
- PUBT · Jul 8 at 07:02 AM
Seres Therapeutics explores partnerships to advance SER-155 development in immune checkpoint inhibitor-related enterocolitis
